Saint Peter's University Hospital Unaudited Balance Sheet (000's)

	09/30/22
Assets	
Current assets:	
Cash and cash equivalents	\$27,140
Short-term investments	33,647
Patient accounts receivable, net	55,310
Assets whose use is limited, current portion	170,271
Supplies Estimated third party payor sottlements, current	7,473
Estimated third-party payer settlements, current portion	12,507
Due from related parties, current portion, net	8,632
Other current assets	11,394
Total current assets	326,374
	,-
Assets whose use is limited, less current portion	14,435
Estimated third-party payer settlements less current	
portion	1,347
Beneficial interest in Foundation	12,195
Right to use leased assets	3,746
Property, plant, equipment and construction, net Due from related parties, non current portion	152,380 1,846
Other assets	27,746
Other assets	\$540,069
•	
Liabilities and net assets	
Current liabilities:	#0.40 5
Current portion of long-term debt and line of credit Current portion of lease liability	\$8,165
Accounts payable	663 20,491
Accrued expenses and other liabilities	40,711
Accrued interest	1,730
Estimated third-party payer settlements, current	1,122
portion	24,105
Due to related parties	17,705
Total current liabilities	113,570
Long-term debt, less current portion	112,229
Long-term portion of right to use leases	3,083
Accrued pension liability	110,815
Estimated third-party payer settlements, less	
current portion	1,686
Other liabilities	28,592
Total liabilities	369,975
Net assets: Net assets without donor restrictions	157 151
Net assets with donor restrictions	157,154 12,940
Total net assets	170,094
101411101 400010	\$540,069
;	Ψ5-10,000

Saint Peter's University Hospital Unaudited Statement of Operations and Changes in Net Assets (000's)

(000°S)	00/20/20
	<u>09/30/22</u>
Revenue, gains and other support:	
Net patient service revenue	\$396,921
Other operating revenue, net	19,287
HHS stimulus	8,771
Total revenue, gains and other support	424,979
Total Totalida, gaine and and capper	12 1,070
Expenses:	
Salaries and wages, net of variable agency labor	180,381
Variable agency labor	10,977
Resident and physician fees	9,703
Employee benefits	41,768
Supplies and expenses	111,061
Governmental taxes, fees, and assessments	14,597
Interest	5,527
Depreciation and amortization	19,785
Total expenses	393,799
Income from operations	31,180
Equity in net earnings of joint ventures	397
Loss on disposal of property, plant and equipment	(8)
Net change in unrealized gains and losses on equity investments	(15,691)
Non-operating net periodic pension cost	728
Excess of revenue over expenses	16,606
Net change in unrealized gains and losses on non-equity	
investments	(9,616)
Donated Equipment and other	612
Increase in net assets without donor restrictions	7,602
Net assets with donor restrictions:	
Restricted gifts and contributions	(4)
Net change in beneficial interest in Foundation	(535)
Increase in net assets with donor restrictions	(539)
Increase in net assets	7,063
Net assets at beginning of year	163,031
Net assets at end of period	\$170,094
'	Ψ.7.0,001

Saint Peter's University Hospital Unaudited Statement of Operations and Changes in Net Assets (000's)

	3rd Quarter 2022
Revenue, gains and other support:	
Net patient service revenue	\$133,666
Other operating revenue, net	6,320
HHS stimulus	0
Total revenue, gains and other support	139,986
Expenses:	
Salaries and wages, net of variable agency labor	62,198
Variable agency labor	2,208
Resident and physician fees	3,141
Employee benefits	13,639
Supplies and expenses	38,481
Governmental taxes, fees, and assessments	4,872
Interest	1,771
Depreciation and amortization	6,595
Total expenses	132,905
Income from operations	7,081
Equity in net earnings of joint ventures	127
Loss on disposal of property, plant and equipment	0
Net change in unrealized gains and losses on equity investments	(3,740)
Non-operating net periodic pension cost	235
Excess of revenue over expenses	3,703
Net change in unrealized gains and losses on non-equity	
investments	(3,216)
Donated Equipment and other	173
Increase in net assets without donor restrictions	660
Net assets with donor restrictions:	
Restricted gifts and contributions	1
Net change in beneficial interest in Foundation	(591)
Increase in net assets with donor restrictions	(590)
Increase in net assets	70
Net assets at beginning of year	0
Net assets at end of period	\$70

Saint Peter's University Hospital Unaudited Statement of Cash Flows (000's)

Increase in net assets \$7,063 Depreciation and amortization 19,785 Net change in unrealized gains and losses on investments 25,307 Net change in beneficial interest in Foundation 535 Donated equipment (612) Changes in operating assets and liabilities Patient accounts receivable (5,643) Supplies and other current assets 376 Due from related parties, net 224 Other assets 890 Accounts payable, accrued expenses, accrued interest and other liabilities (4,090) Estimated third-party payer settlements (23,547) Accrued pension liability (6,665) Net cash provided by operating activities 397 Net (sales) purchases of assets whose use is limited (37,352) Purchases of property, plant, equipment and construction (14,950) Net cash used by investing activities (5,1905) Financing activities: Proceeds from the issuance of debt (137) Repayment of debt and capital leases (7,879) Net cash used by financing activities (46,298) Cash & cash equivalents and restricted cash and restricted cash equivalents, beginning of year 7,006 Cash & cash equivalents and restricted cash and restricted cash equivalents, September 30, 2022 Reconciliation of cash and cash equivalents and restricted cash equivalents, September 30, 2022 Reconciliation of cash and cash equivalents and restricted cash equivalents, September 30, 2022 Restricted cash equivalents Restricted cash equivalents and restricted cash and restricted cash equivalents, September 30, 2022 Restricted cash equivalents Restricted cash equivalents and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash equivalents and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash equivalents and restricted cash and restricted cash equivalents at end of year to the balance sheet	Operating activities	09/30/22
Net change in unrealized gains and losses on investments Net change in beneficial interest in Foundation Donated equipment Changes in operating assets and liabilities Patient accounts receivable Changes in operating assets and liabilities Patient accounts receivable Country assets Due from related parties, net Other assets Accounts payable, accrued expenses, accrued interest and other liabilities Estimated third-party payer settlements Accrued pension liability Accrued pension liability Met cash provided by operating activities Investing activities: Cash received from joint ventures Net (sales) purchases of assets whose use is limited Accash sport, equipment and construction Net cash used by investing activities Financing activities: Proceeds from the issuance of debt Repayment of debt and capital leases Net cash used by financing activities Net increase in cash and cash equivalents and restricted cash and restricted cash equivalents Cash & cash equivalents and restricted cash and restricted cash equivalents, beginning of year Cash & cash equivalents and restricted cash and restricted cash and crestricted cash and cash equivalents and restricted cash and restricted cash and restricted cash and cash equivalents and restricted cash and restricted cash and restricted cash and cash equivalents, September 30, 2022 Reconciliation of cash and cash equivalents and restricted cash and restricted cash and cash equivalents and restricted cash and restricted cash and cash equivalents and restricted cash and restricted cash and cash equivalents and restricted cash and restricted cash and cash equivalents and restricted cash and restricted cash and cash equivalents and restricted cash and restricted cash and cash equivalents and restricted cash and restricted cash and eash equivalents and restricted cash and restricted cash and cash equivalents and restricted cash and restricted cash and cash equivalents and restricted cash and restricted cash and cash equivalents and restricted cash and restricted	Increase in net assets	\$7,063
Net change in beneficial interest in Foundation Donated equipment Changes in operating assets and liabilities Patient accounts receivable Patient accounts receivable Changes and other current assets Supplies a	Depreciation and amortization	19,785
Donated equipment (612) Changes in operating assets and liabilities Patient accounts receivable (5,643) Supplies and other current assets 376 Due from related parties, net 224 Other assets 890 Accounts payable, accrued expenses, accrued interest and other liabilities (4,090) Estimated third-party payer settlements (23,547) Accrued pension liability (6,665) Net cash provided by operating activities 397 Act sales) purchases of assets whose use is limited (37,352) Purchases of property, plant, equipment and construction (14,950) Net cash used by investing activities (51,905) Financing activities: Proceeds from the issuance of debt (137) Repayment of debt and capital leases (7,879) Net cash used by financing activities (8,016) Net increase in cash and cash equivalents and restricted cash and restricted cash equivalents, beginning of year (236,478) Cash & cash equivalents and restricted cash and restricted cash equivalents, September 30, 2022 (33,708) Reconciliation of cash and cash equivalents and restricted cash and restricted cash equivalents, September 30, 2022 (33,708) Restricted cash equivalents and reatricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Reconciliation of cash and cash equivalents and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash & cash equivalents and restricted cash and restricted cash and cash equivalents and restricted cash and restricted cash equivalents and restricted cash and restricted cash equivalents and restricted cash and restricted cash and restricted cash and restricted cash equivalents and restricted cash and restricted cash equivalents and restricted cash and restricted cash and cash equivalents and restricted cash and restricted cash equivalents and restricted cash and restricted cash and restricted cash equivalents and restricted cash and restricted cash equi	Net change in unrealized gains and losses on investments	25,307
Changes in operating assets and liabilities Patient accounts receivable (5,643) Supplies and other current assets 376 Due from related parties, net 224 Other assets 890 Accounts payable, accrued expenses, accrued interest and other liabilities (4,090) Estimated third-party payer settlements (23,547) Accrued pension liability (6,665) Net cash provided by operating activities 397 Net (sales) purchases of assets whose use is limited (37,352) Purchases of property, plant, equipment and construction (14,950) Net cash used by investing activities (51,905) Financing activities: Proceeds from the issuance of debt (137) Repayment of debt and capital leases (7,879) Net cash used by financing activities (8,016) Net increase in cash and cash equivalents and restricted cash and restricted cash equivalents, beginning of year (230,708) Cash & cash equivalents and restricted cash and restricted cash equivalents, september 30, 2022 Reconciliation of cash and cash equivalents and restricted cash and restricted cash and restricted cash equivalents and restricted cash and restricted cash and restricted cash equivalents and restricted cash and restricted cash and restricted cash equivalents and restricted cash and restricted cash and restricted cash equivalents an	Net change in beneficial interest in Foundation	535
Patient accounts receivable Supplies and other current assets 376 Due from related parties, net 224 Other assets 890 Accounts payable, accrued expenses, accrued interest and other liabilities (4,090) Estimated third-party payer settlements (23,547) Accrued pension liability Net cash provided by operating activities Investing activities: Cash received from joint ventures Net (sales) purchases of assets whose use is limited (37,352) Purchases of property, plant, equipment and construction Net cash used by investing activities Financing activities: Proceeds from the issuance of debt Repayment of debt and capital leases Net cash and cash equivalents and restricted cash and restricted cash equivalents, beginning of year Cash & cash equivalents and restricted cash and restricted cash equivalents, september 30, 2022 Reconciliation of cash and cash equivalents and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash equivalents and restricted cash and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash & cash equivalents and restricted cash and restricted cash and restricted cash and cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash & cash equivalents and restricted cash and restricted cash and cash equivalents and cash equivalents and restricted cash and restricted cash and cash equivalents and restricted cash and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Supplemental disclosure of cash flow information	Donated equipment	(612)
Patient accounts receivable Supplies and other current assets 376 Due from related parties, net 224 Other assets 890 Accounts payable, accrued expenses, accrued interest and other liabilities (4,090) Estimated third-party payer settlements (23,547) Accrued pension liability Net cash provided by operating activities Investing activities: Cash received from joint ventures Net (sales) purchases of assets whose use is limited (37,352) Purchases of property, plant, equipment and construction Net cash used by investing activities Financing activities: Proceeds from the issuance of debt Repayment of debt and capital leases Net cash and cash equivalents and restricted cash and restricted cash equivalents, beginning of year Cash & cash equivalents and restricted cash and restricted cash equivalents, september 30, 2022 Reconciliation of cash and cash equivalents and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash equivalents and restricted cash and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash & cash equivalents and restricted cash and restricted cash and restricted cash and cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash & cash equivalents and restricted cash and restricted cash and cash equivalents and cash equivalents and restricted cash and restricted cash and cash equivalents and restricted cash and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Supplemental disclosure of cash flow information	Changes in operating assets and liabilities	
Supplies and other current assets Due from related parties, net 224 Other assets Accounts payable, accrued expenses, accrued interest and other liabilities Estimated third-party payer settlements Accrued pension liability Net cash provided by operating activities Investing activities: Cash received from joint ventures Asset used by investing activities Financing activities: Proceeds from the issuance of debt Repayment of debt and capital leases Act ash equivalents and restricted cash and restricted cash equivalents, beginning of year Cash & cash equivalents and restricted cash and restricted cash equivalents, September 30, 2022 Reconciliation of cash and cash equivalents and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash and cash equivalents and restricted cash and restricted cash and cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash & cash equivalents and restricted cash and restricted cash and cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash & cash equivalents and restricted cash and restricted cash and cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash & cash equivalents and restricted cash and restricted cash and cash equivalents and cash equivalents and restricted cash and restricted cash and cash equivalents and cash equivalents and restricted cash and restricted cash and restricted cash and cash equivalents and restricted cash and restricted cash and restricted cash and restricted cash equivalents and eash equivalents and restricted cash equivalents Supplemental disclosure of cash flow information		(5,643)
Due from related parties, net Other assets 890 Accounts payable, accrued expenses, accrued interest and other liabilities Estimated third-party payer settlements (23,547) Accrued pension liability (6,665) Net cash provided by operating activities Investing activities: Cash received from joint ventures 397 Net (sales) purchases of assets whose use is limited (37,352) Purchases of property, plant, equipment and construction Net cash used by investing activities Financing activities: Proceeds from the issuance of debt Repayment of debt and capital leases (7,879) Net cash used by financing activities (8,016) Net increase in cash and cash equivalents and restricted cash and restricted cash equivalents, beginning of year Cash & cash equivalents and restricted cash and restricted cash equivalents, September 30, 2022 Reconciliation of cash and cash equivalents and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash & cash equivalents and restricted cash and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash & cash equivalents and restricted cash and restricted cash and cash equivalents and cash equivalents and restricted cash and restricted cash and cash equivalents at end of year to the balance sheet Cash & cash equivalents Supplemental disclosure of cash flow information	Supplies and other current assets	
Accounts payable, accrued expenses, accrued interest and other liabilities (4,090) Estimated third-party payer settlements (23,547) Accrued pension liability (6,665) Net cash provided by operating activities 13,623 Investing activities: Cash received from joint ventures 397 Net (sales) purchases of assets whose use is limited (37,352) Purchases of property, plant, equipment and construction (14,950) Net cash used by investing activities (51,905) Financing activities: Proceeds from the issuance of debt (137) Repayment of debt and capital leases (7,879) Net cash used by financing activities (8,016) Net increase in cash and cash equivalents and restricted cash and restricted cash equivalents, beginning of year (2sh & cash equivalents and restricted cash equivalents, September 30, 2022 \$30,708 Reconciliation of cash and cash equivalents and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Cash & cash equivalents and restricted cash and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash & cash equivalents and restricted cash and restricted cash and cash equivalents and restricted cash and restricted cash equivalents and cash equivalents and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash & cash equivalents - under bond indenture 3,568 Total cash and cash equivalents and restricted cash and restricted cash equivalents equivalents and restricted cash and restricted cash equivalents equivalents and restricted cash and restricted cash equivalents	• •	224
expenses, accrued interest and other liabilities (4,090) Estimated third-party payer settlements (23,547) Accrued pension liability (6,665) Net cash provided by operating activities 13,623 Investing activities: Cash received from joint ventures 397 Net (sales) purchases of assets whose use is limited (37,352) Purchases of property, plant, equipment and construction (14,950) Net cash used by investing activities (51,905) Financing activities: Proceeds from the issuance of debt (137) Repayment of debt and capital leases (7,879) Net cash used by financing activities (8,016) Net increase in cash and cash equivalents and restricted cash and restricted cash equivalents (46,298) Cash & cash equivalents and restricted cash and restricted cash equivalents, beginning of year Cash & cash equivalents and restricted cash and restricted cash equivalents, September 30, 2022 \$30,708 Reconciliation of cash and cash equivalents and restricted cash and restricted cash equivalents, September 30, 2022 \$30,708 Restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash & cash equivalents and restricted cash and restricted cash and cash equivalents and restricted cash and restricted cash equivalents Restricted cash & cash equivalents and restricted cash and restricted cash equivalents \$27,140 Restricted cash & cash equivalents and restricted cash and restricted cash equivalents \$30,708	·	890
expenses, accrued interest and other liabilities (4,090) Estimated third-party payer settlements (23,547) Accrued pension liability (6,665) Net cash provided by operating activities 13,623 Investing activities: Cash received from joint ventures 397 Net (sales) purchases of assets whose use is limited (37,352) Purchases of property, plant, equipment and construction (14,950) Net cash used by investing activities (51,905) Financing activities: Proceeds from the issuance of debt (137) Repayment of debt and capital leases (7,879) Net cash used by financing activities (8,016) Net increase in cash and cash equivalents and restricted cash and restricted cash equivalents (46,298) Cash & cash equivalents and restricted cash and restricted cash equivalents, beginning of year Cash & cash equivalents and restricted cash and restricted cash equivalents, September 30, 2022 \$30,708 Reconciliation of cash and cash equivalents and restricted cash and restricted cash equivalents, September 30, 2022 \$30,708 Restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash & cash equivalents and restricted cash and restricted cash and cash equivalents and restricted cash and restricted cash equivalents Restricted cash & cash equivalents and restricted cash and restricted cash equivalents \$27,140 Restricted cash & cash equivalents and restricted cash and restricted cash equivalents \$30,708	Accounts payable, accrued	
Estimated third-party payer settlements (23,547) Accrued pension liability (6,665) Net cash provided by operating activities 13,623 Investing activities: Cash received from joint ventures 397 Net (sales) purchases of assets whose use is limited (37,352) Purchases of property, plant, equipment and construction (14,950) Net cash used by investing activities (51,905) Financing activities: Proceeds from the issuance of debt (137) Repayment of debt and capital leases (7,879) Net cash used by financing activities (8,016) Net increase in cash and cash equivalents and restricted cash and restricted cash equivalents and restricted cash equivalents, beginning of year Cash & cash equivalents and restricted cash and restricted cash equivalents, September 30, 2022 \$30,708 Reconciliation of cash and cash equivalents and restricted cash and restricted cash equivalents, September 30, 2022 \$30,708 Reconciliation of cash and cash equivalents and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash & cash equivalents - under bond indenture 3,568 Total cash and cash equivalents and restricted cash and restricted	· ·	
settlements (23,547) Accrued pension liability (6,665) Net cash provided by operating activities 13,623 Investing activities: Cash received from joint ventures 397 Net (sales) purchases of assets whose use is limited (37,352) Purchases of property, plant, equipment and construction (14,950) Net cash used by investing activities (51,905) Financing activities: Proceeds from the issuance of debt (137) Repayment of debt and capital leases (7,879) Net cash used by financing activities (8,016) Net increase in cash and cash equivalents and restricted cash and restricted cash equivalents and restricted cash and restricted cash equivalents, beginning of year Cash & cash equivalents and restricted cash and restricted cash equivalents, September 30, 2022 \$30,708 Reconciliation of cash and cash equivalents and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash ace equivalents and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash ace equivalents - under bond indenture 3,568 Total cash and cash equivalents and restricted cash and restricted cash equivalents Supplemental disclosure of cash flow information		(4,090)
Accrued pension liability Net cash provided by operating activities Investing activities: Cash received from joint ventures Net (sales) purchases of assets whose use is limited (37,352) Purchases of property, plant, equipment and construction Net cash used by investing activities Financing activities: Proceeds from the issuance of debt Repayment of debt and capital leases Net cash used by financing activities Net increase in cash and cash equivalents and restricted cash and restricted cash equivalents Cash & cash equivalents and restricted cash and restricted cash equivalents, beginning of year Cash & cash equivalents and restricted cash equivalents, September 30, 2022 Reconciliation of cash and cash equivalents and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Cash & cash equivalents and restricted cash and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash & cash equivalents and restricted cash and restricted cash and cash equivalents and restricted cash and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Supplemental disclosure of cash flow information		(00 5 47)
Investing activities: Cash received from joint ventures Net (sales) purchases of assets whose use is limited (37,352) Purchases of property, plant, equipment and construction Net cash used by investing activities Financing activities: Proceeds from the issuance of debt Repayment of debt and capital leases Net cash used by financing activities (37,879) Net cash used by financing activities (46,298) Net increase in cash and cash equivalents and restricted cash and restricted cash equivalents and restricted cash equivalents and restricted cash equivalents, beginning of year Cash & cash equivalents and restricted cash and restricted cash equivalents, September 30, 2022 Reconciliation of cash and cash equivalents and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash & cash equivalents and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash & cash equivalents and restricted cash and restricted cash and cash equivalents and restricted cash and restricted cash and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents \$27,140 Restricted cash & cash equivalents and restricted cash and restricted cash equivalents and restricted cash equiv		,
Investing activities: Cash received from joint ventures Net (sales) purchases of assets whose use is limited (37,352) Purchases of property, plant, equipment and construction Net cash used by investing activities Financing activities: Proceeds from the issuance of debt Repayment of debt and capital leases (7,879) Net cash used by financing activities (46,298) Net increase in cash and cash equivalents and restricted cash and restricted cash equivalents Cash & cash equivalents and restricted cash and restricted cash equivalents, beginning of year Cash & cash equivalents and restricted cash and restricted cash equivalents, September 30, 2022 Reconciliation of cash and cash equivalents and restricted cash and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash & cash equivalents - under bond indenture Total cash and cash equivalents and restricted cash and restricted cash and cash equivalents and restricted cash and restricted cash and cash equivalents and restricted cash and restricted cash and restricted cash and restricted cash equivalents \$27,140 Restricted cash & cash equivalents - under bond indenture Total cash and cash equivalents and restricted cash and restricted cash equivalents Supplemental disclosure of cash flow information	•	
Cash received from joint ventures Net (sales) purchases of assets whose use is limited (37,352) Purchases of property, plant, equipment and construction Net cash used by investing activities Financing activities: Proceeds from the issuance of debt Repayment of debt and capital leases Net cash used by financing activities (37,352) Financing activities: Proceeds from the issuance of debt Repayment of debt and capital leases (7,879) Net cash used by financing activities (8,016) Net increase in cash and cash equivalents and restricted cash and restricted cash equivalents Cash & cash equivalents and restricted cash and restricted cash equivalents, beginning of year Cash & cash equivalents and restricted cash and restricted cash equivalents, September 30, 2022 Reconciliation of cash and cash equivalents and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash & cash equivalents - under bond indenture Total cash and cash equivalents and restricted cash and restricted cash and cash equivalents and restricted cash and restricted cash equivalents \$27,140 Restricted cash & cash equivalents and restricted cash and restricted cash equivalents \$30,708 Supplemental disclosure of cash flow information	Net cash provided by operating activities	13,623
Net (sales) purchases of assets whose use is limited (37,352) Purchases of property, plant, equipment and construction (14,950) Net cash used by investing activities (51,905) Financing activities: Proceeds from the issuance of debt (137) Repayment of debt and capital leases (7,879) Net cash used by financing activities (8,016) Net increase in cash and cash equivalents and restricted cash and restricted cash equivalents (46,298) Cash & cash equivalents and restricted cash and restricted cash equivalents, beginning of year (2ash & cash equivalents and restricted cash and restricted cash equivalents, September 30, 2022 \$30,708 Reconciliation of cash and cash equivalents and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents \$27,140 Restricted cash & cash equivalents - under bond indenture 3,568 Total cash and cash equivalents and restricted cash and restricted cash and cash equivalents and restricted cash and restricted cash equivalents \$30,708	Investing activities:	
Purchases of property, plant, equipment and construction Net cash used by investing activities Financing activities: Proceeds from the issuance of debt Repayment of debt and capital leases Net cash used by financing activities Net increase in cash and cash equivalents and restricted cash and restricted cash equivalents Cash & cash equivalents and restricted cash and restricted cash equivalents, beginning of year Cash & cash equivalents and restricted cash and restricted cash equivalents, September 30, 2022 Reconciliation of cash and cash equivalents and restricted cash and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash & cash equivalents - under bond indenture Total cash and cash equivalents and restricted cash and restricted cash and cash equivalents Supplemental disclosure of cash flow information (14,950) (51,905) (51,905) (51,905) (51,905) (51,905) (6,177) (8,016) (8,016) (8,016) (7,879) (8,016) (9,016) (9,016) (9,016) (9,016) (14,950) (9,17) (9,017)	Cash received from joint ventures	397
Net cash used by investing activities (51,905) Financing activities: Proceeds from the issuance of debt (137) Repayment of debt and capital leases (7,879) Net cash used by financing activities (8,016) Net increase in cash and cash equivalents and restricted cash and restricted cash equivalents (46,298) Cash & cash equivalents and restricted cash and restricted cash equivalents, beginning of year (77,006) Cash & cash equivalents and restricted cash and restricted cash equivalents, September 30, 2022 \$30,708 Reconciliation of cash and cash equivalents and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents \$27,140 Restricted cash and cash equivalents - under bond indenture 3,568 Total cash and cash equivalents and restricted cash and restricted cash equivalents Supplemental disclosure of cash flow information	Net (sales) purchases of assets whose use is limited	(37,352)
Financing activities: Proceeds from the issuance of debt (137) Repayment of debt and capital leases (7,879) Net cash used by financing activities (8,016) Net increase in cash and cash equivalents and restricted cash and restricted cash equivalents (46,298) Cash & cash equivalents and restricted cash and restricted cash equivalents, beginning of year 77,006 Cash & cash equivalents and restricted cash and restricted cash equivalents, September 30, 2022 \$30,708 Reconciliation of cash and cash equivalents and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents \$27,140 Restricted cash and cash equivalents - under bond indenture 3,568 Total cash and cash equivalents and restricted cash and restricted cash equivalents Supplemental disclosure of cash flow information	Purchases of property, plant, equipment and construction	(14,950)
Proceeds from the issuance of debt Repayment of debt and capital leases Net cash used by financing activities Net increase in cash and cash equivalents and restricted cash and restricted cash equivalents Cash & cash equivalents and restricted cash and restricted cash equivalents, beginning of year Cash & cash equivalents and restricted cash and restricted cash equivalents, September 30, 2022 Reconciliation of cash and cash equivalents and restricted cash and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash & cash equivalents - under bond indenture Total cash and cash equivalents and restricted cash and restricted cash and cash equivalents and restricted cash and restricted cash equivalents Supplemental disclosure of cash flow information	Net cash used by investing activities	(51,905)
Repayment of debt and capital leases Net cash used by financing activities Net increase in cash and cash equivalents and restricted cash and restricted cash equivalents Cash & cash equivalents and restricted cash and restricted cash equivalents, beginning of year Cash & cash equivalents and restricted cash and restricted cash equivalents, September 30, 2022 Reconciliation of cash and cash equivalents and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Cash & cash equivalents - under bond indenture Total cash and cash equivalents and restricted cash and restricted cash and cash equivalents and restricted cash and restricted cash equivalents Supplemental disclosure of cash flow information	Financing activities:	
Net cash used by financing activities (8,016) Net increase in cash and cash equivalents and restricted cash and restricted cash equivalents (46,298) Cash & cash equivalents and restricted cash and restricted cash equivalents, beginning of year 77,006 Cash & cash equivalents and restricted cash and restricted cash equivalents, September 30, 2022 \$30,708 Reconciliation of cash and cash equivalents and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents \$27,140 Restricted cash & cash equivalents - under bond indenture 3,568 Total cash and cash equivalents and restricted cash and restricted cash equivalents Supplemental disclosure of cash flow information	Proceeds from the issuance of debt	(137)
Net increase in cash and cash equivalents and restricted cash and restricted cash equivalents (46,298) Cash & cash equivalents and restricted cash and restricted cash equivalents, beginning of year Cash & cash equivalents and restricted cash and restricted cash equivalents, September 30, 2022 Reconciliation of cash and cash equivalents and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash & cash equivalents - under bond indenture Total cash and cash equivalents and restricted cash and restricted cash equivalents Supplemental disclosure of cash flow information (46,298) (77,006) (77,006) (830,708)	Repayment of debt and capital leases	(7,879)
Cash & cash equivalents and restricted cash and restricted cash equivalents, beginning of year Cash & cash equivalents and restricted cash and restricted cash equivalents, September 30, 2022 Reconciliation of cash and cash equivalents and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Cash & cash equivalents Restricted cash & cash equivalents - under bond indenture Total cash and cash equivalents and restricted cash and restricted cash equivalents Supplemental disclosure of cash flow information (46,298) (46,298) (46,298)	Net cash used by financing activities	(8,016)
equivalents, beginning of year Cash & cash equivalents and restricted cash and restricted cash equivalents, September 30, 2022 Reconciliation of cash and cash equivalents and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash & cash equivalents - under bond indenture Total cash and cash equivalents and restricted cash and restricted cash equivalents Supplemental disclosure of cash flow information 77,006 \$30,708		(46,298)
equivalents, beginning of year Cash & cash equivalents and restricted cash and restricted cash equivalents, September 30, 2022 Reconciliation of cash and cash equivalents and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash & cash equivalents - under bond indenture Total cash and cash equivalents and restricted cash and restricted cash equivalents Supplemental disclosure of cash flow information 77,006 \$30,708	Cash & cash equivalents and restricted cash and restricted cash	
equivalents, September 30, 2022 Reconciliation of cash and cash equivalents and restricted cash and restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash & cash equivalents - under bond indenture Total cash and cash equivalents and restricted cash and restricted cash equivalents Supplemental disclosure of cash flow information \$30,708	·	77,006
restricted cash equivalents at end of year to the balance sheet Cash & cash equivalents Restricted cash & cash equivalents - under bond indenture Total cash and cash equivalents and restricted cash and restricted cash equivalents Supplemental disclosure of cash flow information \$27,140 \$3,568 \$30,708	•	\$30,708
Restricted cash & cash equivalents - under bond indenture 3,568 Total cash and cash equivalents and restricted cash and restricted cash equivalents Supplemental disclosure of cash flow information	·	
Total cash and cash equivalents and restricted cash and restricted cash equivalents \$30,708 Supplemental disclosure of cash flow information	Cash & cash equivalents	\$27,140
Total cash and cash equivalents and restricted cash and restricted cash equivalents \$30,708 Supplemental disclosure of cash flow information	·	
· ·	Total cash and cash equivalents and restricted cash and restricted	
Cash paid for interest \$7.443	Supplemental disclosure of cash flow information	
Cash paid for interest	Cash paid for interest	\$7,443